Shandong Cancer Hospital and Institute
4 clinical trials · 4 recruiting · OTHER
Trials by Shandong Cancer Hospital and Institute
RECRUITINGNCT06261047
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
Recent years have seen significant advancements in the treatment landscape of advanced hepatocellular carcinoma (HCC), with the emergence of targeted and immunotherapy strategies...
Sponsor: Shandong Cancer Hospital and InstituteEnrolling: 361 location
Hepatocellular CarcinomaRadiotherapy
RECRUITINGPhase 2NCT06398405
A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer
The investigators conduct this phase II study to evaluate safety and effectiveness of EGCG in patients with dysphagia. Swallowing-related dysphagia and pain scores were recorded...
Sponsor: Shandong Cancer Hospital and InstituteEnrolling: 721 location
Esophageal CancerDysphagia, EsophagealEpigallocatechin Gallate
RECRUITINGPhase 2NCT06816771
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory...
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.
Sponsor: Shandong Cancer Hospital and InstituteEnrolling: 381 location
Rhabdomyosarcoma, Recurrent, Refractory
RECRUITINGNCT06980259
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma
This study is a multicenter, prospective, randomized controlled phase II clinical trial designed to evaluate the efficacy and safety of Spatially Fractionated Radiation Therapy...
Sponsor: Shandong Cancer Hospital and InstituteEnrolling: 1061 location
Soft Tissue Sarcoma (STS)